Predictive markers of response to Motixafortide, Cemiplimab, Gemcitabine and Nab-Paclitaxel in untreated metastatic pancreatic cancer
Official title: Predictive Markers of Response to and Treatment Effects of Motixafortide, Cemiplimab, Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Metastatic Pancreatic Cancer
Funded at Sloan-Kettering Inst Can Research · NIH-11391413 · Data updated 2026-11-12
This grant tests a combination therapy for people with newly diagnosed metastatic pancreatic cancer to see which patients respond best.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 22, 2025 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $109,080 |
| NIH project number | 5K38CA304069-03 |
| Project ID | NIH-11391413 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with treatment-naïve metastatic pancreatic adenocarcinoma eligible for GN-based regimens and willing to undergo biopsies for biomarker studies.
✕Less likely to help
Patients not matching the biomarker profile or who experience intolerable toxicity may not derive benefit from this specific combination.
What this research studies
In this study, patients with treatment‑naïve metastatic pancreatic adenocarcinoma will receive a combination of motixafortide, cemiplimab, gemcitabine andnab-paclitaxel, with the goal of improving outcomes. Researchers will use tumor biopsies and advanced sequencing to identify CXCR4/CXCL12-related markers that may predict response. The trial is a phase II, multicenter, randomized comparison against standard GN therapy, focusing on progression-free survival and other clinical endpoints. The work aims to link immune and stromal biology in the tumor microenvironment to treatment effectiveness. Participation will involve standard chemotherapy administration, biomarker collection, and follow-up visits to monitor safety and efficacy.
Why it matters
Potential benefit: If successful, patients with metastatic pancreatic cancer could receive a more effective, tailored therapy and clearer guidance on who is most likely to benefit.
How similar studies have gone: Early phase data showed encouraging responses and a correlation between CXCL12/CXCR4-related biology and treatment response in a small cohort.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: May, Michael Stevenson — Sloan-Kettering Inst Can Research
- Study coordinator: May, Michael Stevenson
Related research
Other NIH-funded projects on the same topics.
-
Targeting barriers to treat metastatic pancreatic cancer
Aims to combine local radiotherapy with a targeted immunotherapy delivered directly into pancreatic tumors to overcome treatment resistance and stop metastasis in patients with pancreatic cancer.
-
Personalized multi‑antigen T‑cell therapy for metastatic pancreatic cancer after FOLFIRINOX
Patients with metastatic pancreatic cancer who have completed FOLFIRINOX receive a personalized T‑cell treatment made from their own blood that targets several tumor proteins to help the immune system attack the cancer.
-
Investigating the role of Engrailed-1 in metastatic pancreatic cancer
This study is looking at how a protein called Engrailed-1 (EN1) affects the growth and spread of pancreatic cancer, with the hope of finding new ways to treat this tough disease.
-
Using patient-derived T cells to target pancreatic cancer after chemotherapy
This study is testing a new treatment called MT-601, which uses specially modified T cells from your own blood to help fight metastatic pancreatic cancer after you've had FOLFIRINOX chemotherapy, with the hope of improving how well your body can target and control the cancer.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.